Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis

SUMMARY: We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database. Differences were noted in sex, age, pathologic fractures, comorbidity index, and prior bisphosphonate use fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Imel, E.A., Starzyk, K., Gliklich, R., Weiss, R.J., Wang, Y., Williams, S.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661401/
https://www.ncbi.nlm.nih.gov/pubmed/32696118
http://dx.doi.org/10.1007/s00198-020-05388-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661401/
https://www.ncbi.nlm.nih.gov/pubmed/32696118
http://dx.doi.org/10.1007/s00198-020-05388-y

Ejemplares similares